BBA
HRMY icon

Baker Bros. Advisors’s Harmony Biosciences HRMY Stock Holding History

Baker Bros. Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-123,600
Closed -$6.03M – 119
2022
Q2 		$6.03M Hold
123,600
– – 0.03% 76
2022
Q1 		$6.01M Hold
123,600
– – 0.03% 81
2021
Q4 		$5.27M Hold
123,600
– – 0.03% 92
2021
Q3 		$4.74M Hold
123,600
– – 0.02% 96
2021
Q2 		$3.49M Hold
123,600
– – 0.02% 102
2021
Q1 		$4.08M Sell
123,600
-56,400
-31% -$1.98M 0.02% 101
2020
Q4 		$6.51M Sell
180,000
-220,000
-55% -$8.88M 0.02% 86
2020
Q3 		$13.6M Buy
+400,000
New +$14.6M 0.05% 62

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Baker Bros. Advisors's HRMY Position: Q3 2022 in Review

Baker Bros. Advisors sold out of Harmony Biosciences (HRMY) in Q3 2022, closing a stake of 123,600 shares — an estimated $6.03M sold.

Baker Bros. Advisors first reported a position in HRMY in Q3 2020 and held it in 8 quarters. The position peaked at $13.6M in Q3 2020. 203 funds tracked by Wall St. Rank hold HRMY as of Q3 2022.

  • Baker Bros. Advisors reported no remaining Harmony Biosciences position as of Q3 2022 after selling out during the quarter.
  • Baker Bros. Advisors sold 123,600 Harmony Biosciences shares in Q3 2022, an estimated $6.03M.
  • Baker Bros. Advisors first reported a position in Harmony Biosciences in Q3 2020 and held it in 8 quarters.
  • Baker Bros. Advisors's Harmony Biosciences position peaked at $13.6M in Q3 2020.
  • 203 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2022.

Based on Baker Bros. Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.